Royal Bank Of Canada initiated coverage on shares of BIOVERATIV INC (NASDAQ:BIVV) in a report issued on Thursday. The brokerage issued a sector perform rating and a $59.00 price objective on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. Jefferies Group LLC reissued a buy rating and issued a $70.00 price objective (up from $67.00) on shares of BIOVERATIV INC in a research note on Wednesday, August 9th. Cowen and Company reissued a buy rating and issued a $80.00 price objective on shares of BIOVERATIV INC in a research note on Friday, August 4th. Wedbush reissued a market perform rating on shares of BIOVERATIV INC in a research note on Wednesday, June 28th. William Blair assumed coverage on shares of BIOVERATIV INC in a research note on Wednesday, June 28th. They issued a market perform rating for the company. Finally, Credit Suisse Group raised shares of BIOVERATIV INC from an underperform rating to a neutral rating and lifted their price objective for the stock from $47.00 to $52.00 in a research note on Wednesday, May 24th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $60.33.

BIOVERATIV INC (BIVV) traded down 1.75% during mid-day trading on Thursday, reaching $55.45. 591,780 shares of the company’s stock traded hands. BIOVERATIV INC has a 12-month low of $41.88 and a 12-month high of $57.82. The stock has a market capitalization of $6.00 billion and a PE ratio of 13.18. The stock has a 50-day moving average price of $56.67 and a 200-day moving average price of $54.23.

BIOVERATIV INC (NASDAQ:BIVV) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.17. The company had revenue of $289.10 million for the quarter, compared to analysts’ expectations of $269.00 million. The business’s revenue was up 37.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.59 earnings per share. Equities research analysts expect that BIOVERATIV INC will post $2.89 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “BIOVERATIV INC (BIVV) Now Covered by Analysts at Royal Bank Of Canada” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/15/bioverativ-inc-bivv-now-covered-by-analysts-at-royal-bank-of-canada.html.

In other news, insider Diantha Duvall sold 818 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total value of $49,464.46. Following the completion of the sale, the insider now owns 2,128 shares in the company, valued at approximately $128,680.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Brian S. Posner bought 1,000 shares of the stock in a transaction dated Wednesday, August 9th. The stock was purchased at an average price of $59.19 per share, with a total value of $59,190.00. Following the acquisition, the director now directly owns 6,693 shares in the company, valued at approximately $396,158.67. The disclosure for this purchase can be found here.

BIOVERATIV INC Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Analyst Recommendations for BIOVERATIV INC (NASDAQ:BIVV)

Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with MarketBeat.com's FREE daily email newsletter.